normal phenotype
|
• viable and fertile with no signs of neuropathy or motor weakness
|
|
hm1
|
Slc12a6tm1Garo/Slc12a6tm1Garo
B6.129-Slc12a6tm1Garo |
|
|||||||||||||||||
|
• viable and fertile with no signs of neuropathy or motor weakness
|
|
cn2
|
Slc12a6tm1Garo/Slc12a6tm1Garo Tg(Syn1-cre)671Jxm/0 involves: 129 * C57BL/6 * CBA |
|
|||||||||||||||||
|
• unable to successfully breed
|
|
• progressive peripheral neuropathy starting at 3-4 weeks of age
|
|
• at 2 months of age
|
|
• hypoplastic with a small but significant decrease in length
|
|
• axon swelling in sciatic nerves
|
|
• axon degeneration, hypomyelination and axon swelling in sciatic nerves
|
|
• hypomyelination in sciatic nerves
|
|
• in sciatic nerves
|
|
• by 3-4 weeks of age
|
|
• severe locomotor deficiencies
• deficiencies become more severe after 8 months of age
|
|
• significant increase in the total distance traveled and the number of movement bouts at 5 months of age
|
|
• significantly less sensitive in a formalin test of spontaneous chemical/inflammatory pain
|
|
• at 2 months of age
|
|
• significantly less sensitive in a formalin test of spontaneous chemical/inflammatory pain
|
Mouse Models of Human Disease |
OMIM ID | Ref(s) | |
| Agenesis of the Corpus Callosum with Peripheral Neuropathy; ACCPN | 218000 | J:183239 | |